<DOC>
	<DOCNO>NCT01899989</DOCNO>
	<brief_summary>The purpose study determine use exploratory immunologic biomarkers , functional MRI image serve early predictor response NSCLC . It also provide important information perceive side effect patient perspective . Patients may participate tumor ≥3 cm without lymph node involvement ( chemotherapy part standard care ) . Patients receive stereotactic body radiation therapy ( SBRT ) per standard dose guideline .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Inoperable Locally-advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>All patient : Histologically confirm nonsmall cell lung cancer Medically technically inoperable per thoracic surgeon patient 's preference undergo surgical resection Age ≥ 18 year Women childbearing potential must negative blood pregnancy test Ability provide write informed consent Cohort A : Stage IIAIIIA ( TanyN1M0 T2b4N0M0 ) Selected patient single station N2 nodal involvement close proximity primary tumor target may consider eligible discretion PI normal tissue guideline meet Eligible chemotherapy Karnofsky Performance Status ≥70 % Men woman childbearing potential must willing use effective contraception treatment least 3 month thereafter Patients must show adequate organ function define : Calculated creatinine clearance ≥40 mL/min patient receive pemetrexed ( CockcroftGault ) Calculated creatinine clearance ≥30 mL/min patient receive gemcitabine paclitaxel ( CockcroftGault ) Total bilirubin le 1.5 x ULN ( unless know Gilbert 's disease ) AST ALT le 3 x ULN Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Cohort B : T2a4N0M0 candidate cohort A treated chemotherapy ( due patient preference recommendation treat physician ) . All patient : Prior radiation therapy lung Prior surgery chemotherapy presentation lung cancer ( history prior lung cancer treat deem inactive clinician acceptable . Recurrent tumor may treat protocol long SBRT definitive treatment . ) N23 lymph node involvement base PET/EBUSFNA/mediastinoscopy ( Any N2 disease minimal single station involvement exclude ) Direct tumor extension include aorta pulmonary artery Chronic corticosteroid use equivalent ≥ prednisone 10 mg daily Prior treatment CD137 agonist , ipilimumab , CTLA4 inhibitor , PD1/PDL1 inhibitor Unstable congestive heart failure Cohort A : Continuous oxygen use Patients meeting follow exclusion criterion exclude functional MRI portion : Metallic implant , exclusion determine per institutional policy Pacemaker defibrillator exclude Stents etc . evaluate accord MSKCC policy Unmanageable claustrophobia High risk nephrogenic systemic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stereotactic Body Radiation Therapy ( SBRT )</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>13-113</keyword>
</DOC>